STOCK TITAN

Agilent Technologies Inc Stock Price, News & Analysis

A NYSE

Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.

Agilent Technologies Inc (A) delivers cutting-edge analytical instruments and laboratory solutions for scientific advancement across biopharmaceutical, diagnostic, and environmental sectors. This page provides investors and industry professionals with a centralized source for all official company announcements and market-relevant developments.

Access real-time updates on Agilent's financial performance, strategic partnerships, product innovations, and regulatory milestones. Our curated news collection includes earnings releases, executive leadership updates, R&D breakthroughs, and industry event coverage—all essential for tracking the company's impact on life sciences and laboratory technology.

Key focus areas include advancements in genomic research tools, sustainability initiatives in lab operations, and cross-sector collaborations driving scientific discovery. Bookmark this page to stay informed about Agilent's evolving role in enabling precision medicine, environmental testing, and next-generation materials analysis.

Rhea-AI Summary

Agilent Technologies (NYSE: A) has awarded the prestigious Agilent Thought Leader Award to Dr. David R. Liu, a notable researcher in genome editing. This recognition aims to support Dr. Liu's groundbreaking work on CRISPR applications and genetic diseases. Agilent's funding will enhance research into molecular editing tools such as base and prime editing, which target genetic disorders. Dr. Liu expressed gratitude for the support, while Agilent emphasized its commitment to advancing CRISPR methodologies and genomics profiling tools, contributing to significant scientific advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
none
-
Rhea-AI Summary

Agilent Technologies (NYSE: A) has signed a worldwide distribution agreement with Visiopharm to co-market AI-driven precision pathology software alongside Agilent's automated staining solutions. This collaboration, initially focused on Europe, marks Agilent's entry into the digital pathology market, which is projected to double in adoption by 2030. The COVID-19 pandemic has accelerated this trend as pathologists increasingly use remote reporting. The partnership aims to enhance diagnostic accuracy and workflow efficiency for pathologists, contributing to improved patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
-
Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) will participate in the Wells Fargo Virtual Healthcare Conference on Sept. 9, 2021, featuring a live webcast discussion with Mike McMullen, President and CEO, and Bob McMahon, CFO. The event is scheduled for 11:20 a.m. ET / 8:20 a.m. PT. Links for the webcast will be available on the Agilent Investor Relations website, with a replay accessible afterward. Agilent is known for its contributions to life sciences, diagnostics, and applied chemical markets, having generated $5.34 billion in revenue in fiscal year 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
conferences
Rhea-AI Summary

Agilent Technologies (NYSE: A) announced the expanded use of its PD-L1 IHC 22C3 pharmDx assay in Europe, now CE-IVD marked for identifying esophageal cancer patients eligible for KEYTRUDA treatment with a Combined Positive Score (CPS) ≥ 10. This assay supports treatment for patients with locally advanced unresectable or metastatic esophageal carcinoma. In 2020, almost 53,000 esophageal cancer cases were reported in Europe. The PD-L1 assay is crucial for enhancing diagnostic confidence as more patients qualify for anti-PD-1 therapies like KEYTRUDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
-
Rhea-AI Summary

Agilent Technologies (NYSE: A) supports research by IIT Bombay and QIMR Berghofer on a new method to distinguish between severe and mild COVID-19 patients. Using the Agilent Cary 630 FTIR Spectrometer, researchers analyzed blood plasma from 160 patients and developed a classification algorithm. The method showed 69.2% specificity and 94.1% sensitivity in predicting severe cases. This advancement aims to aid healthcare workers in prioritizing resources efficiently amid ongoing COVID-19 challenges. Agilent's commitment to infectious disease research is underscored by this collaboration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
covid-19
-
Rhea-AI Summary

Agilent Technologies reported $1.59 billion in revenue for Q3 2021, marking a 26% year-over-year increase. GAAP net income was $264 million or 86 cents per share, up from $199 million or 64 cents in Q3 2020. Non-GAAP net income rose to $337 million or $1.10 per share, compared to $243 million or 78 cents a year ago. The company raised its revenue outlook for FY 2021 to between $6.29 billion and $6.32 billion and expects Q4 revenue of $1.63 billion to $1.66 billion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) has achieved Great Place to Work certification, based on feedback from 5,679 U.S. employees. An impressive 86% reported Agilent as a great workplace, significantly higher than the 59% benchmark for typical U.S. companies. The recognition underscores Agilent's commitment to fairness, equity, and integrity, reflected in high scores for treatment of employees across various demographics. Additionally, Agilent is recognized globally, having won similar awards in China, Germany, India, and Spain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
-
Rhea-AI Summary

Agilent Technologies (NYSE: A) has established in-country manufacturing for its SureSelect portfolio at its Hangzhou, China facility. This move aims to enhance delivery turnaround times for next-generation sequencing assays, allowing faster development and optimization of custom panels. The new manufacturing site will maintain the same high-quality standards as U.S. counterparts, enabling quicker customer access to assay technology. Agilent's investment reflects its commitment to growth opportunities in the China market and reinforces its genomics capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
-
Rhea-AI Summary

Agilent Technologies (NYSE: A) announced the 2021 Early Career Professor Award recipient, Dr. Jason H. Yang, from Rutgers New Jersey Medical School. This award focuses on innovative solutions for managing immunological responses to diseases. Dr. Yang's research combines high-throughput experimentation with machine learning to develop engineered macrophages as therapies for infections, autoimmunity, and cancer. The award supports his cutting-edge research and strengthens Agilent's commitment to advancing scientific innovation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
none
Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) announced a study published in the journal Lung Cancer, highlighting the effectiveness of next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) for detecting ALK fusions in lung cancer patients. Conducted in collaboration with Resolution Bioscience and Memorial Sloan Kettering Cancer Center, the study emphasizes the non-invasive nature and clinical utility of this method. Findings suggest that ctDNA testing can monitor resistance mechanisms in patients undergoing targeted therapy, supporting precision oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none

FAQ

What is the current stock price of Agilent Technologies (A)?

The current stock price of Agilent Technologies (A) is $113.92 as of July 18, 2025.

What is the market cap of Agilent Technologies (A)?

The market cap of Agilent Technologies (A) is approximately 35.3B.
Agilent Technologies Inc

NYSE:A

A Rankings

A Stock Data

35.27B
283.14M
0.29%
91.65%
1.2%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States
SANTA CLARA